指南与共识临床免疫质量管理与危急值分子诊断

IFCC关于SARS-CoV-2抗体血清学检测的临时指南

IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2.
指南 / 共识 · Clin Chem Lab Med · 2020-10-07

国际临床化学和实验室医学联盟(IFCC)COVID-19工作组发布临时指南,针对SARS-CoV-2抗体血清学检测,提出临床适应证与目标人群、方法选择、方法学评价及结果解释与局限性四方面建议。该指南基于证据,为临床实验室在选择、验证和实施血清学检测方法时提供实践指导。

要点

  • 指南涵盖血清学检测的临床适应证和目标人群。
  • 需关注血清学方法的选择、评价及结果解释与局限性。
  • 推荐为临床实验室提供方法选择、验证和实施的实践指导。

核心结论

  • IFCC COVID-19工作组基于证据提出SARS-CoV-2抗体血清学检测的临时指南,为实验室方法选择、验证和实施提供实践指导。

研究设计与样本

  • 由国际临床化学和实验室医学联盟(IFCC)COVID-19工作组制定。

关键数值与推荐

  • 指南涵盖临床适应证与目标人群、方法选择、方法学评价、结果解释与局限性四方面内容。

临床怎么用

  • 临床实验室可依据该指南进行血清学方法的选择、验证和实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serological testing for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as an important component of the clinical management of patients with coronavirus disease 2019 (COVID-19) as well as the epidemiological assessment of SARS-CoV-2 exposure worldwide. In addition to molecular testing for the detection of SARS-CoV-2 infection, clinical laboratories have also needed to increase testing capacity to include serological evaluation of patients with suspected or known COVID-19. While regulatory approved serological immunoassays are now widely available from diagnostic manufacturers globally, there is significant debate regarding the clinical utility of these tests, as well as their clinical and analytical performance requirements prior to application. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay evaluation, and (D) test interpretation and limitations for serological testing of antibodies against SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories in the selection, verification, and implementation of serological assays and are of the utmost importance as we expand our pandemic response from initial case tracing and containment to mitigation strategies to minimize resurgence and further morbidity and mortality.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Bohn MK, Loh TP, Wang CB, et al. IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2. Clin Chem Lab Med. 2020. PMID: 33027043. doi:10.1515/cclm-2020-1413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。